Uttiya Deb

Uttiya Deb

Auto-generated profile, based on publicly available information

Uttiya Deb

Medical Affairs, Johnson & Johnson Private Limited, Mumbai, Maharashtra, 400080, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
UDUttiya Deb
Uttiya Deb
SBSupreeti Biswas
Supreeti Biswas

18 August 2023 in Expert Review of Hematology
Verified
Journal Article
Open access
SYSanjeev Yadav
Sanjeev Yadav
SGSadashivudu Gundeti
Sadashivudu Gundeti
ABAbhay Bhave
Abhay Bhave
UDUttiya Deb
Uttiya Deb
JDJitendra Dixit
Jitendra Dixit
KMkundan mishra
kundan mishra
The prevalence of multiple myeloma (MM) has gradually increased over the last few decades in India due to growing population, better disease awareness and improved diagnostic procedures. Despite such advances, MM remains an incurable and relapsing disease due to its heterogeneity and genomic instability. With the inclusion of monoclonal antibodies, especially daratumumab in the frontline regimen, the management landscape of MM has improved significantly resulting in better disease control and patient outcomes. This review aims to provide an in-depth summary of efficacy and safety of frontline daratumumab therapy in treatment of MM including patients with high-risk cytogenetic profile. Based on the review of literature, daratumumab in frontline therapy has demonstrated improved efficacy in terms of reduction in disease progression or death, and superior minimal residual disease (MRD)-negativity rates with an acceptable safety profile in patients with newly diagnosed MM (NDMM) including patients with high-risk cytogenetic profile. Daratumumab alone or in combination with other drugs has shown similar clinical outcomes in patients with relapsed/refractory MM. Hence, daratumumab can be used upfront in patients with MM.

2 March 2021 in Future Oncology
Verified
Journal Article
Closed access
UDUttiya Deb
Uttiya Deb
SMSandip Mukhopadhyay
Sandip Mukhopadhyay
BBBiswamit Bhattacharya
Biswamit Bhattacharya
SBSanatan Banerjee
Sanatan Banerjee
SBSupreeti Biswas
Supreeti Biswas
The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL). A prospective ran... Lay abstract Cancer-related fatigue is a common and nagging problem that needs best evidence-based management. Modafinil, a brain stimulant, and dexamethasone, a corticosteroid, have been shown in ... Tweetable abstract Oral doses of the #psychostimulant #modafinil and #corticosteroid #dexamethsasone can improve #cancer-related #fatigue and #qualityoflife without major #sideeffects. #Modafinil w...

20 December 2023 in Future Oncology
Verified
Journal Article
Open access
LKLalit Kumar
Lalit Kumar
SMSameer Melinkeri
Sameer Melinkeri
PGPrasanth Ganesan
Prasanth Ganesan
JKJeevan Kumar
Jeevan Kumar
GBGhanashyam Biswas
Ghanashyam Biswas
JDJitendra Dixit
Jitendra Dixit
Aim: To assess the safety and effectiveness of daratumumab monotherapy in Indian patients with relapsed/refractory multiple myeloma. Methods: In this prospective, multicenter, phase IV study, patie... Plain language summary Daratumumab is a monoclonal antibody approved for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). This study evaluated the outcome of daratumumab ... Tweetable abstract This study demonstrated an acceptable and expected safety profile with consistent efficacy for daratumumab monotherapy in patients with relapsed/refractory multiple myeloma, prov...

1 October 2022 in Indian Journal of Cancer
Verified
Journal Article
Open access
UDUttiya Deb
Uttiya Deb
SMSandip Mukhopadhyay
Sandip Mukhopadhyay
SBSanatan Banerjee
Sanatan Banerjee
SBSupreeti Biswas
Supreeti Biswas
Background: Granulocyte-colony stimulating factor (G-CSF) is used in cancer patients to treat chemotherapy-induced neutropenia (CIN). However, G-CSF poses few risks. Despite the regular use of G-CSF in CIN management, there is a paucity of published data on its safety profile in the management of CIN in India. Hence, the present study was designed to demonstrate the safety profile of G-CSF in patients with CIN. Methods: A prospective observational study was conducted over a period of 5 months enrolling 100 cancer patients aged from 18 years to 70 years. Patients with a diagnosis of CIN who received G-CSF were included. Patients were followed up for 15 days. Adverse events (AEs) were graded according to US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The system organ class and preferred term of Medical Dictionary for Regulatory Activities (MedDRA) were used for reporting the AEs. Causality assessment was done by using the WHO-Uppsala Monitoring Centre scale. Results: The most frequently reported AEs were musculoskeletal and connective tissue disorders which included bone pain, myalgia, arthralgia, and pain in the extremity. Other AEs reported were general disorders and administration site conditions, and gastrointestinal disorders. The highest grade of toxicity reported was of grade 3 among all AEs. The majority of AEs had a “probable” type of causality relationship with G-CSF. Conclusion: G-CSF has a safety profile consistent with previous G-CSF studies.

22 October 2019 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
UDUttiya Deb
Uttiya Deb
SRSoumya Ray
Soumya Ray
SBSupreeti Biswas
Supreeti Biswas
Ciprofloxacin is a commonly used fluoroquinolone group of antimicrobial which is used for treating infective conditions like community acquired pneumonia and urinary tract infections. A patient of cataract was treated with ciprofloxacin eye drop as her pre-operative medication. She presented after four days with itching and redness in her right eye with swelling of the peri-orbital skin. We report this rare case where topical application of ciprofloxacin was responsible for the ocular symptoms.